Search
What Shionogi’s planned acquisition of IntraBio means for the NPC community
Shionogi has entered into an agreement to acquire IntraBio, the company behind AQNEURSA® (levacetylleucine). Here is what the announcement means—and what we are still waiting to learn—for the Australian NPC community.
ANPDF
Oct 73 min read
Second treatment approved by FDA for Niemann-Pick disease, type C: Introducing AQNEURSA
FDA approval of AQNEURSA offers new hope for Australian families with Niemann-Pick disease, promising better treatment and quality of life.
ANPDF
Sep 25, 20244 min read